

## 業績目録

平成17年12月5日

### ・ PK/PDモデル関係の原著

1. Hirunpanich V, Katagi J, Sethabouppha B, Sato H. : Demonstration of docosahexaenoic acid (DHA) as a bioavailability enhancer for CYP3A substrates: in vitro and in vivo evidence using cyclosporine in rats. *Drug Metab Dispos.*, in press (2005).
2. Ito S, Kawamura T, Inada M, Inoue Y, Hirao Y, Koga T, Kunizaki J, Shimizu T, Sato H.: Physiologically based pharmacokinetic modelling of the three-step metabolism of pyrimidine using C-uracil as an in vivo probe. *Br J Clin Pharmacol.* **60**(6):584-93 (2005).
3. Inada M, Hirao Y, Koga T, Itose M, Kunizaki J, Shimizu T, Sato H.: Relationships among plasma [2-(13)C]uracil concentrations, breath (13)CO(2) expiration, and dihydropyrimidine dehydrogenase (DPD) activity in the liver in normal and dpd-deficient dogs. *Drug Metab Dispos.* **33**(3):381-7 (2005).
4. Hirunpanich V, Utaipat A, Morales NP, Bunyaphatsara N, Sato H., Herunsale A, Suthisisang C. : Hypocholesterolemic and antioxidant effects of aqueous extracts from the dried calyx of *Hibiscus sabdariffa* L. in hypercholesterolemic rats. *J Ethnopharmacol.*, in press (2005).
5. Hirunpanich V, Utaipat A, Morales NP, Bunyaphatsara N, Sato H., Herunsalee A, Suthisisang C.: Antioxidant effects of aqueous extracts from dried calyx of *Hibiscus sabdariffa* Linn. (Roselle) in vitro using rat low-density lipoprotein (LDL). *Biol Pharm Bull.* **28**(3):481-4 (2005).
6. Shitara Y, Sato H., Sugiyama Y.: Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. *Annu Rev Pharmacol Toxicol.* **45**: 689-723 (2005).
7. Minematsu T, Sugiyama E, Kusama M, Hori S, Yamada Y, Ohtani H, Sawada Y, Sato H., Takayama T, Sugawara Y, Makuuchi M, Iga T.: Effect of hematocrit on pharmacokinetics of tacrolimus in adult living donor liver transplant recipients. *Transplant Proc.* **36**(5):1506-11 (2004).
8. Shitara Y, Hirano M, Adachi Y, Itoh T, Sato H., Sugiyama Y.: In vitro and in vivo correlation of the inhibitory effect of cyclosporin A on the transporter-mediated hepatic uptake of cerivastatin in rats. *Drug Metab Dispos.* **32**(12):1468-75 (2004).
9. Shitara Y, Hirano M, Sato H., Sugiyama Y. : Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. *J Pharmacol Exp Ther.* **311**(1): 228-36 (2004).
10. Y. Shitara, H. Sato., and Y. Sugiyama: Evaluation of Drug-Drug Interaction in the

Hepatobiliary and Renal Transport of Drugs, *Pharmacol. Toxicol.* **45**:689-723 (2004).

11. Shitara Y, Itoh T, Sato H, Li AP, Sugiyama Y : Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. *J Pharmacol Exp Ther.* **304**(2):610-6 (2003).

12. Atsumi M, Kawakami J, Sugiyama E, Kotaki H, Sawada Y, Sato H, Yamada Y, Iga T. : Pharmacokinetic and pharmacodynamic analyses, based on dopamine D2-receptor occupancy of bromocriptine, of bromocriptine-induced contralateral rotations in unilaterally 6-OHDA-lesioned rats. *Synapse* **50**(2):110-6 (2003).

13. Hanada E, Ohtani H, Hirota M, Uemura N, Nakaya H, Kotaki H, Sato H, Yamada Y, Iga T. : Inhibitory effect of erythromycin on potassium currents in rat ventricular myocytes in comparison with disopyramide. *J Pharm Pharmacol.* **55**(7):995-1002 (2003).

14. Tsujikawa K, Dan Y, Nogawa K, Sato H, Yamada Y, Murakami H, Ohtani H, Sawada Y, Iga T.: Potentiation of domperidone-induced catalepsy by a P-glycoprotein inhibitor, cyclosporin A. *Biopharm Drug Dispos.* **24**(3):105-14 (2003).

15. Cullingford TE, Eagles DA, and Sato H : The ketogenic diet upregulates expression of the gene encoding the key ketogenic enzyme mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase in rat brain. *Epilepsy Res.* **49**: 99-107 (2002).

16. Cullingford TE, Dolphin CT, and Sato H.: The peroxisome proliferator-activated receptor alpha-selective activator ciprofibrate upregulates expression of genes encoding fatty acid oxidation and ketogenesis enzymes in rat brain. *Neuropharmacology.* **42**:724-30 (2002).

17. Yamada Y, Ohno Y, Nakashima Y, Fukuda M, Takayanagi R, Sato H, Tsuchiya F, Sawada Y, and Iga T: Prediction and assessment of extrapyramidal side effects induced by risperidone based on dopamine D(2) receptor occupancy. *Synapse.* **6**: 32-7 (2002).

18. Minematsu T, Ohtani H, Yamada Y, Sawada Y, Sato H, Iga T. : Quantitative relationship between myocardial concentration of tacrolimus and QT prolongation in guinea pigs: pharmacokinetic/pharmacodynamic model incorporating a site of adverse effect. *J Pharmacokinetic Pharmacodyn.* **28**(6):533-54 (2001).

19. Ohno Y, Yamada Y, Usu T, Takahashi K, Tsuchiya F, Ohtani H, Sato H, Sawada Y, Iga T.: Pharmacokinetic and pharmacodynamic analysis of the antihypercalcemic effect of incadronate disodium in rats. *Biol Pharm Bull.* **24**(11):1290-3 (2001).

20. Ohtani H, Odagiri Y, Sato H, Sawada Y, Iga T. A comparative pharmacodynamic study of the arrhythmogenicity of antidepressants, fluvoxamine and imipramine, in guinea pigs. *Biol Pharm Bull.* **24**(5): 550-554 (2001).

21. Y. Sakamoto. Sakamoto Y, Makuuchi M, Harihara Y, Imamura H, and Sato H. Higher intracerebral concentration of tacrolimus after intermittent than continuous administration to rats. *Liver Transpl.* **7**:1071-6 (2001).

22. Ohtani H, Taninaka C, Hanada E, Kotaki H, Sato H, Sawada Y, Iga T: Comparative pharmacodynamic analysis of Q-T interval prolongation induced by the macrolides clarithromycin, roxithromycin, and azithromycin in rats. *Antimicrob Agents Chemother.*, **44**(10):2630-7 (2000).
23. Hirota M, Ohtani H, Hanada E, Sato H, Kotaki H, Uemura H, Nakaya H, Iga T: Influence of extracellular K<sup>+</sup> concentrations on quinidine-induced K<sup>+</sup> current inhibition in rat ventricular myocytes. *J Pharm Pharmacol.*, **52**(1):99-105 (2000).
24. Sawamura R, Sato H, Kawakami J, Iga T: Inhibitory effect of azole antifungal agents on the glucuronidation of lorazepam using rabbit liver microsomes in vitro. *Biol Pharm Bull.*, **23**(5):669-71 (2000).
25. Sakamoto Y, Makuuchi-M, Harihara Y, Imamura H, Sato H: Correlation between neurotoxic events and intracerebral concentration of tacrolimus in rats. *Biol Pharm Bull.* **23**(8):1008-10 (2000).
26. H. Ohtani, H. Sato, T. Iga, H. Kotaki, Y. Sawada: Pharmacokinetic-pharmacodynamic analysis of the arrhythmogenic potency of a novel antiallergic agent, ebastine, in rats. *Biopharm Drug Dispos.* **20**(2):101-106 (1999).
27. H. Ohtani, E. Hanada, M. Hirota, H. Sato, H. Kotaki, Y. Sawada, H. Uemura, H. Nakaya, and T. Iga: Inhibitory effects of antihistamines epinastine, terfenadine, and ebastine on potassium currents in rats. *J. Pharm. Pharmacol.*, **51**: 1059-63 (1999).
28. Katashima M, Yamada Y, Yamamoto K, Kotaki H, Sato H, Sawada Y, Iga: Analysis of antiplatelet effect of ticlopidine in humans : Modeling based on irreversible inhibition of platelet precursor in the bone marrow. *J Pharmacokinet Biopharm.*, **27**(3):283-96 (1999).
29. T. Minematsu, H. Ohtani, H. Sato, and T. Iga: Sustained QT prolongation induced by tacrolimus in guinea pigs. *Life Sci.*, **65**: PL197-202 (1999).
30. T. Minematsu, H. Ohtani, H. Sato, and T. Iga: Pharmacokinetic/pharmacodynamic analysis of tacrolimus-induced QT prolongation in guinea pigs. *Biol. Pharm. Bull.*, **22**(12):1341-6 (1999).
31. Kusama M, Yamamoto K, Yamada H, Kotaki H, Sato H, Iga T. : Effect of cilastatin on renal handling of vancomycin in rats. *J Pharm Sci.* **87**(9):1173-6 (1998).
32. E. Hanada, H. Ohtani, H. Kotaki, H. Sato, Y. Sawada, and T. Iga: Pharmacodynamic analysis of the electrocardiographic interaction between disopyramide and erythromycin in rats. *J. Pharm. Sci.*, **88**: 234-240 (1998).
33. F.Q. Zhao, N.X. Zheng, H. Sato, I. Adachi, and I. Horikoshi: Pharmacokinetics of a Chinese traditional medicine, Danchensu (3,4-dihydroxyphenyllactic acid), in rabbits using high-performance liquid chromatography, *Biol. Pharm. Bull.*, **20**: 285-287 (1997).

34. K. Shinoda, H. Sato, I. Adachi, and I. Horikoshi: Disposition of liposomal cepharanthine after intraperitoneal administration in mice, *Xenob. Metabol. Dispos.*, **12**: 1-4 (1997).
35. M. Sakai, K. Nagashima, H. Iinuma, K. Hara, T. Tamura, and H. Sato: Effect of age on the pharmacokinetics of oral isosorbide mononitrate and dinitrate in patients with ischemic heart disease. *Jpn. J. Ther. Drug Monitor.*, **14**: 253-259 (1997).
36. N.X. Zheng, H. Sato, I. Adachi, and I. Horikoshi: Pharmacokinetic and pharmacodynamic modeling of a thromboxane synthetase inhibitor, ozagrel, in human. *Japn. J. Hosp. Pharm.* **22**, 26-37 (1996).
37. N.X. Zheng, H. Sato, I. Adachi, and I. Horikoshi. Rectal absorption of a novel thromboxane synthetase inhibitor, DP-1904, in rabbits. *J. Pharm. Sci. Technol.(Yakuzaigaku)*, **56**, 85-91 (1996).
38. H. Sato, Y. Sugiyama, A. Tsuji, and I. Horikoshi: Importance of receptor-mediated endocytosis (RME) in peptide delivery and targeting: Kinetic aspect. *Advanced Drug Delivery Reviews*, **19**, 445-467 (1996).
39. H. Sato, S. Sato, Y.M. Wang, and I. Horikoshi: Add-in macros for rapid and versatile calculation of non-compartmental pharmacokinetic parameters on Microsoft Excel spreadsheets. *Comp. Methods Prog. Biomed.*, **50**, 43-52 (1996).
40. N.X. Zheng, H. Sato, I. Adachi, I. Kanamoto, and I. Horikoshi: Pharmacokinetic-pharmacodynamic modelling of a novel thromboxane synthetase inhibitor, DP-1904, in rabbits. *Eur. J. Drug Metab. Pharmacokin.*, **28**, 285-293 (1996).
41. S. Charnick, R. Kawai, J. Nedelman, M. Lemaire, W. Nederberber, and H. Sato: Physiologically based pharmacokinetic (PBPK) modeling as a tool for drug development. *J. Pharmacokin. Biopharm.* **23**, 217-229 (1995).
42. H. Sato and I. Horikoshi: The use of Macintosh for simulation and parameter optimization: application to clinical pharmacokinetics. *Medicial Care & Computer* **7**, 325-328 (1995).
43. N.X. Zheng, H. Sato, I. Adachi, and I. Horikoshi: Pharmacokinetic and pharmacodynamic modeling of a novel thromboxane synthetase inhibitor, DP-1904, in human. *Xonobiotic Metab. Dispos.* **10**, 799-802 (1995).
44. N.X. Zheng, H. Sato, I. Adachi, I. Kanamoto, and I. Horikoshi. Pharmacokinetic and pharmacodynamic studies of ozagrel in rabbits. *Biol. Pharm. Bull.* **18**, 1738-1743 (1995).
45. H. Sato, T. Terasaki, H. Mizuguchi, K. Okumura, and A. Tsuji: Receptor-recycling model of clearance and distribution of insulin in the perfused mouse liver. *Diabetologia* **34**, 613-621 (1991).
46. Sugiyama, Y., Kim, D.C., Satoh, H., Yanai, S., Sato, H., Iga, T., and Hanano, M.: Receptor-mediated disposition of polypeptides: Kinetic analysis of the transport of epidermal growth factor as a model peptide using in vitro isolated perfused organs and in vivo system. *J.*

*Controlled Release* **13**, 157-174 (1990).

47. A. Tsuji, H. Sato, I. Tamai, H. Adachi, T. Nishihara, M. Ishiguro, N. Ohnuma, and T. Noguchi: Physiologically based pharmacokinetics of a new penem, SUN5555, for evaluation of in vivo efficacy. *Drug Metab. Dispos.* **18**, 245-252 (1990).

48. Nagata, M. Murata, T. Terasaki, H. Sato, and A. Tsuji: Physiological pharmacokinetics of a new muscle-relaxant, inaperisone, combined with its pharmacological effect on blood flow rate. *Drug Metab. Dispos.* **18**, 902-910 (1990).

49. E. Nakashima, F. Ishikawa, H. Sato, Y. Deguchi, I. Tamai, R. Matsushita, F. Ichimura, and A. Tsuji: Kinetics of peritoneal drug transport in rats: An application of the pore theory of transcapillary exchange. *J. Pharm. Sci.* **77**, 481-488 (1988).

50. H. Sato, E. Okezaki, S. Yamamoto, O. Nagata, H. Kato, and A. Tsuji: Entry of the new quinolone antibacterial agents of ofloxacin and NY-198 into the central nervous system in rats. *J. Pharmacobio-Dyn.* **11**, 386-394 (1988).

51. Y. Deguchi, E. Nakashima, F. Ishikawa, H. Sato, I. Tamai, R. Matsushita, Y. Tofuku, F. Ichimura, and A. Tsuji: Peritoneal transport of  $\beta$ -lactam antibiotics: Effects of plasma protein binding and the interspecies relationship. *J. Pharm. Sci.* **77**, 559-564 (1988).

52. H. Sato, F. Ishikawa, E. Okezaki, O. Nagata, E. Nakashima, Y. Deguchi, F. Ichimura, and A. Tsuji: Kinetic analysis of the peritoneal transport of quinolonocarboxylic acids in rats. *Chem. Pharm. Bull.* **36**, 3180-3185 (1988).

53. O. Nagata, T. Terasaki, E. Yada, H. Sato, I. Tamai, and A. Tsuji: Degradation kinetics of ( $\pm$ )-4'-ethyl-2-methyl-3-(1-pyrrolidinyl) propiophenone hydrochloride (HY-770) and structure-stability relationship among its analogues in aqueous solution. *J. Pharm. Sci.* **78**, 57-61 (1988).

54. S. Miyauchi, Y. Sugiyama, H. Sato, Y. Sawada, T. Iga, and M. Hanano: Effect of a diffusional barrier to a metabolite across hepatocytes on its kinetics in "enzyme-distributed" models: A computer-aided simulation study. *J. Pharmacokin. Biopharm.* **15**, 399-421 (1987).

55. H. Sato, Y. Sugiyama, Y. Sawada, T. Iga, and M. Hanano: Physiologically based pharmacokinetics of radioiodinated human  $\beta$ -endorphin in rats. An application of the capillary membrane-limited model. *Drug Metab. Dispos.* **15**, 540-550 (1987).

56. H. Sato, Y. Sugiyama, S. Miyauchi, Y. Sawada, T. Iga, and M. Hanano: A simulation study on the effect of a uniform diffusional barrier across hepatocytes on drug metabolism by evenly or unevenly distributed uni-enzyme in the liver. *J. Pharm. Sci.* **75**, 3-8 (1986).

57. H. Sato, Y. Sugiyama, Y. Sawada, T. Iga, and M. Hanano: Pharmacokinetic study of exogenously (1984).

## ・著書（共著・分担執筆）

1. 辻 彰、寺崎哲也、佐藤 均, 生理学的薬物速度論, 「医薬品の開発 19 巻 (薬動学)」, p.119-228, 小泉 保編, 広川書店, 東京 (1990).
2. 佐藤 均, 受容体介在性エンドサイトーシス, 「続医薬品の開発 4 巻 (薬物の生体膜輸送と組織標的化)」, p.271-297, 寺田 弘, 辻 彰編, 広川書店, 東京 (1991).
3. 佐藤 均, 受容体介在性エンドサイトーシスを利用したドラッグデリバリー, 「続医薬品の開発 4 巻 (薬物の生体膜輸送と組織標的化)」, p.559-570, 寺田 弘, 辻 彰編, 広川書店, 東京 (1991).
4. 佐藤 均, 毛細血管透過性を利用したドラッグデリバリー, 「続医薬品の開発 4 巻 (薬物の生体膜輸送と組織標的化)」, p.597-620, 寺田 弘, 辻 彰編, 広川書店, 東京 (1991).
5. 佐藤 均, 汎用動態解析プログラム S-CALC, 「続医薬品の開発 6 巻 (薬物動態評価法とコンピュータ)」, p.53-80, 田中 久, 山岡 清編, 広川書店, 東京 (1991).
6. 佐藤 均, 肺灌流解析, 「続医薬品の開発 6 巻 (薬物動態評価法とコンピュータ)」, p.61-77, 田中 久, 山岡 清編, 広川書店, 東京 (1991).
9. 佐藤 均, 「医療薬学 I. 臨床薬物動態学」、共立出版、東京 (1993).
13. 佐藤 均「薬剤学 改訂第 6 版」(共著)南江堂、東京 (2002).
14. H. Sato and T. Iga: "Drug Interactions for Labeling", page 80-93 in "Preclinical and Clinical Evaluations of Drug-Drug Interactions" (Albert P. Li and Yuichi Sugiyama, Ed. ISE Press, Baltimore, USA (2002)).

## ・総説

1. H. Sato: Recent advances in drug transfer across the blood-brain barrier. I. *Pharm Tech Japan* 9: 273-279 (1993).
2. H. Sato: Recent advances in drug transfer across the blood-brain barrier. II. *Pharm Tech Japan* 9: 407-412 (1993).
3. 佐藤 均、堀越 勇: マッキントッシュを用いたシミュレーションおよびパラメータ最適化—薬物動態研究・教育への応用を中心として, *ファルマシア*, 30: 50-54 (1994).
4. 佐藤 均、堀越 勇: Macintoshによるシミュレーション及びパラメータ最適化: 臨床薬物動態学への応用, *医療とコンピュータ*, 7: 325-328 (1995).
5. 佐藤 均、鄭 年新、足立伊佐雄、堀越 勇: 間接作用モデル (Indirect Response Model) を用いた体内動態 / 薬効動態の解析, *医薬ジャーナル*, 11, 211-216 (1996).

6. 佐藤 均: 今後 ,期待されるバイオ医薬品, 薬局(「バイオ医薬品」特集号), 48: 739-750, 1997.
7. 佐藤 均: ヒトインスリン様成長因子-I, 薬局(「バイオ医薬品」特集号), 48: 825-837, 1997.
8. 佐藤 均、伊賀立二: インターネットによる薬物間相互作用データベース構築と情報提供、ファーマシートゥデイ, 11: 26-29, 1998.
9. 佐藤 均、伊賀立二: 薬物間相互作用の基礎知識 - 分布過程 -, 薬局(特大号「薬物間相互作用と服薬指導」), 49: 69-78, 1998.
10. 川上純一、佐藤 均、伊賀立二: 薬物間相互作用の基礎知識 - ファーマコダイナミックな相互作用 -, 薬局(特大号「薬物間相互作用と服薬指導」), 49: 79-90, 1998.
11. 川上純一、佐藤 均、伊賀立二: 薬物間相互作用: 予測と回避のための環境づくり 薬物間相互作用の臨床 1: ニューキノロン系抗菌薬、治療学, 32: 315-326, 1998.
12. 佐藤 均、伊賀立二: 薬物間相互作用の基礎 薬物分布における相互作用, 治療学, 32, 291-299, 1998.
13. 高柳理早、山田安彦、佐藤 均、伊賀立二: 薬物間相互作用と服薬指導 薬物間相互作用回避のための医薬品情報収集のノウハウ: 病院薬剤部における医薬品情報収集、薬局, 49: 92-104, 1998.
14. メトクロプラミドによるプロラクチン放出のPK/PDモデル解析 山本康次郎, 萩野真実, 小滝一, 佐藤 均, 伊賀立二 臨床薬理の進歩 21: 89-97 (2000).
15. 佐藤 均, 伊賀立二、ヒトにおける薬物動態とその変動要因の基礎知識 薬物動態の基本的な表現法 クリアランスの生理解剖学的意味とは? どう算出する? どう活用する? 月刊薬事 42(4):681-693, 2000.
16. 佐藤 均、伊賀立二、薬物相互作用情報の添付文書への反映 - 病院薬剤部の立場から -. 薬物動態 15(3):250-254, 2000.
17. 青木公子, 設楽悦久, 佐藤 均, 杉山雄一: 薬物動態を制御するトランスポーター 病態時における発現変動, *Molecular Medicine* 41(12):1552-1566 (2004).
18. 青木公子, 設楽悦久, 佐藤 均, 杉山雄一: 薬物動態を制御するトランスポーター 発現ならびに機能制御の機構 転写過程での調節(解説), *Molecular Medicine* 42(1): 90-99 (2004).
19. 青木公子, 設楽悦久, 佐藤 均, 杉山雄一: 薬物動態を制御するトランスポーター 発現ならびに機能制御の機構 タンパク質合成後の調節, *Molecular Medicine* 42(2): 218-225 (2005).
20. 設楽悦久, 佐藤 均, 杉山雄一: 薬物トランスポーターによる肝臓・消化管における薬物曝露量の制御は可能であるか? *分子消化器病* 2(1): 27-33 (2005).